BIOMANUFACTURING BIOLOGICS FOR A BRIGHTER FUTURE
Bondi’s manufacturing and delivery platform is based on bioengineered, food-grade cyanobacteria which offers a cost-effective, self-formulating, and rapidly-scalable solution for a range of therapeutic modalities.
Our platform has great potential in the manufacture and delivery of VLP-based vaccines, therapeutic proteins & peptides, nucleic-acid-based treatments, and monoclonal antibodies for a wide range of diseases.
We simplify manufacturing using whole-cell solutions to significantly reduce complexity and costs, while enabling distributed biomanufacturing and point-of-care production.
Based in Sydney, Australia, we work with leading Australian research groups to develop and test the next generation of biologics.
APPLICATIONS
RELIABLE - ADAPTABLE - SCALABLE
BIOMANUFACTURING BIOLOGICS FOR A BRIGHTER FUTURE
We are developing a novel platform for the manufacture and delivery of biologics for a range of therapeutic modalities.
TECHNOLOGY
BIOENGINEERING THE FUTURE
We use our light and CO2-powered system to rapidly, reliably and safely produce self-formulating biologics in large quantities, at significantly reduced cost & complexity compared to current approaches.
Our technology combines cutting edge bioengineering with the latest advanced applications in health. Our cyanobacteria strains offer fast, controllable growth and ease of genetic manipulation. We use this power to create a flexible, scalable, customisable solution to manufacture and deliver biologics.